Stay updated with breaking news from Neck Oncologist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line...
Nagpur Today : Nagpur News Latest News RST Cancer Hospital organises “Survivor Meet”